OBJECTIVE： To explore clinical efficacy and safety of Zoledronic acid injection combined with Jintiange capsule in the treatment of postmenopausal osteoporosis （PMOP）. METHODS： 99 PMOP patients from Tunchang County People’s Hospital of Hainan Province during Nov. 2012 to Feb. 2015 were selected and divided into control group， single drug group and combination group according to random number table， with 33 cases in each group. Control group received Calcarea carbonica D3 chewable tablets （Ⅱ） 2 tablets， po， qd+Calcitriol soft capsules 0.50 μg， po， bid for osteoporosis； single drug group additionally received Zoledronic acid injection 5 mg，ivgtt，once a year， on the basis of control group； combination group was additionally given Jintiange capsule 1.2 g， po， tid， on the basis of single drug group. 3 groups received treatment for 12 months. BMD， VAS score and ADL score of 3 groups were compared as well as the occurrence of ADR. RESULTS： Before treatment， there was no statistical significance in above indexes of 3 groups （P＞0.05）. After treatment， BMD of single drug group and combination group were increased significantly compared to before treatment， which were significantly higher than that of control group， with statistical significance （P＜0.05）. VAS score and ADL score of knee joint and the small of the back were decreased significantly in single drug group and combination group； the single drug group were significantly lower than the control group （except for ADL score）； the combination group were significantly lower than the single drug group， with statistical significance （P＜0.05）. The incidence of long-term ADR in single drug group and combination group （6.1％， 3.0％） were significantly lower than in control group （21.2％）， with statistical significance （P＜0.05）. CONCLUSIONS： Zoledronic acid injection combined with Jintiange capsules could improve BMD of PMOP patients， relieving pain of knee and back with good safety.